Bendamustine for indolent lymphoma reduces relapse after 10 years

Dr Rummel speaks with ecancer at ASCO 2017 about 10 years of data gathered from across German clinics from patients with indolent lymphoma who were treated with bendamustine rituximab as a first line therapy.
Compared to alternative R-CHOP regimens, the bendamustine data shows equivalent overall survival at 10 years, with less patients relapsing, later.